As of June 21, 2025, Sienna Biopharmaceuticals Inc (SNNAQ) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Sienna Biopharmaceuticals Inc's Gross Margin to Peers
To better understand Sienna Biopharmaceuticals Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Sienna Biopharmaceuticals Inc (SNNAQ) | 7775.20% |
| Context Therapeutics Inc (CNTX) | 7775.20% |
| BiondVax Pharmaceuticals Ltd (BVXV) | 7775.20% |
| Profile Solutions Inc (PSIQ) | 7775.20% |
| Medican Enterprises Inc (MDCN) | 7775.20% |
| Aeolus Pharmaceuticals Inc (AOLS) | 7775.20% |
Compared to its competitors, Sienna Biopharmaceuticals Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.